News

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...
Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, ...
But Eli Lilly's supply woes began to ease earlier this year, and the Food and Drug Administration removed tirzepatide, the active ingredient in Mounjaro and Zepbound, from its shortage list.
The reason for the disappointing sales, according to the company, is not an issue of demand or supply. During an earnings call Wednesday, Eli Lilly instead blamed it on drug wholesalers cutting ...
Eli Lilly filed a complaint with the U.S. International Trade Commission on Thursday to block companies from importing and selling cheaper versions of its blockbuster drug Mounjaro online ...